Fusion Pharmaceuticals Q3 EPS $(0.45) Down From $(0.24) YoY
Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.45) per share. This is a 87.5 percent decrease over losses of $(0.24) per share from the same period last year.
Fusion Pharma To Present At Cantor Global Healthcare Conference Wednesday, Sept. 29 At 2:40 p.m. EDT
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2021
B. Riley Securities Initiates Coverage On Fusion Pharmaceuticals with Buy Rating, Announces Price Target of $17
B. Riley Securities initiates coverage on Fusion Pharmaceuticals (NASDAQ:FUSN) with a Buy rating and announces Price Target of $17.
Morgan Stanley Maintains Overweight on Fusion Pharmaceuticals, Lowers Price Target to $19
Morgan Stanley analyst Matthew Harrison maintains Fusion Pharmaceuticals (NASDAQ:FUSN) with a Overweight and lowers the price target from $20 to $19.
Fusion Pharma Reports Expansion Of R&D Collab With TRIUMF For Actinium Supply Production; Fusion Will Continue Its Investment Of Up To C$25M In TRIUMF
Fusion Pharmaceuticals Inc. (NASDAQ:FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator centre, today
Fusion Pharmaceuticals Q2 EPS $(0.63) Up From $(2.99) YoY
Fusion Pharmaceuticals (NASDAQ:FUSN) reported quarterly losses of $(0.63) per share. This is a 78.93 percent increase over losses of $(2.99) per share from the same period last year.
Fusion Pharma Stock Is Trading Higher As FDA Clears Early-Stage Study For Radiopharmaceutical In Neck, Bladder Cancers
The FDA has signed off Fusion Pharmaceuticals Inc’s (NASDAQ:FUSN) Investigational New Drug (IND) applications for [225Ac]-FPI-1966 (FPI-1966) and imaging agent [111In]-FPI-1967…